Sue-Jean Lin Sells Shares of Arcutis Biotherapeutics

On June 15, 2026, Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT) at an average price of $24.38. The planned sale was valued at about $120,583.

Insider Buying and Selling at Arcutis Biotherapeutics, Inc.

Sue-Jean Lin's sale was part of a planned transaction. On the same day, Howard Welgus sold 4,096 shares at $24.41, and another 4,096 shares were sold at a lower price, also as planned. Welgus also purchased 4,096 shares at approximately $7.93. Earlier, on June 5, Patrick Heron bought 16,667 shares.

Other Institutional Activity in Arcutis Biotherapeutics

Suvretta Capital Management, LLC increased its position in Arcutis Biotherapeutics by 363,000 shares, ending with 12,327,000 shares valued at about $290.4 million. BlackRock, Inc. added 100,832 shares, bringing its total to 9,200,411 shares worth approximately $216.8 million. State Street Corp significantly boosted its holdings by 807,896 shares, now holding 6,296,197 shares valued at roughly $148.3 million.

Arcutis Biotherapeutics, Inc. Stock Up 10.7%

Shares of Arcutis Biotherapeutics are trading near $26.32. The company has a market cap of around $3.21 billion and a forward P/E ratio of 22.21, with a beta of 1.521. The stock's 52-week range is between $13.06 and $31.77, with a 50-day moving average of $22.67 and a 200-day moving average of $23.89. The current ratio stands at 2.684, and the debt-to-equity ratio is 60.465.

Recent Earnings

Arcutis Biotherapeutics reported revenue of $415.6 million with a growth rate of 60.1%. The company posted a slight net margin loss of 0.57% and a return on equity of -1.43%. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

Analysts are optimistic about Arcutis Biotherapeutics, with Mizuho, Guggenheim, and Needham maintaining buy ratings and price targets around $35. HC Wainwright & Co. also kept a buy rating with a $34 target. The consensus recommendation is a strong buy, with a mean target price of $34.63.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company based in Westlake Village, California. It focuses on developing treatments for dermatological diseases. The company's main product, ZORYVE, is a topical cream for plaque psoriasis and atopic dermatitis. It also works on treatments for seborrheic dermatitis and psoriasis. Led by CEO Todd Franklin Watanabe, Arcutis employs 354 people.

Bottom Line

Sue-Jean Lin's planned sale of Arcutis Biotherapeutics shares is part of regular insider activity. Investors watch these moves for insight into company sentiment. While insider trades can be informative, they don't necessarily indicate future stock performance. Analyst ratings remain positive, suggesting confidence in the company's prospects.